Bevacizumab对非神经胶质瘤有用吗？

Title:Is there a Role for Bevacizumab in Non-Glial Tumors?

Volume: 16 Issue: 7

Author(s): Elisa Trevisan, Luca Bertero, Michela Magistrello, Roberta Ruda and Riccardo Soffietti

Affiliation:

关键词: Bevacizumab，脑肿瘤，室管膜瘤，成神经管细胞瘤，脑膜瘤，前庭神经鞘瘤，VEGF。

摘要: Angiogenesis is one of the hallmarks of cancer, including brain tumors. The vascular endothelial growth factor (VEGF) family and their receptors are of utmost importance in the complex interaction between pro- and anti-angiogenic factors, and have a crucial role in tumor angiogenesis. Up to date, targeting the VEGF pathway with specific drugs has yielded interesting results in oncology. In particular bevacizumab (Bev), a humanized monoclonal antibody against VEGF-A, has been approved by the Food and Drug Administration (FDA) for use in recurrent glioblastomas failing standard radiochemotherapy. Bevacizumab is now being extensively investigated in several non-glial brain tumors, such as vestibular schwannomas, meningiomas, ependymomas, medulloblastomas and miscellaneous histotypes. The aim of this review is to reevaluate the literature on the use of Bev in non-glial brain tumors.

Cite this article as:

Elisa Trevisan, Luca Bertero, Michela Magistrello, Roberta Ruda and Riccardo Soffietti , Is there a Role for Bevacizumab in Non-Glial Tumors?, Current Drug Targets 2015; 16 (7) . https://dx.doi.org/10.2174/1389450116666150325230810